ARGX ArGEN-X SE

argenx Announces Annual General Meeting of Shareholders on May 2, 2023

argenx Announces Annual General Meeting of Shareholders on May 2, 2023



March 17, 2023

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that an Annual General Meeting of shareholders will be held at 12:00 PM CET on Tuesday, May 2, 2023 at Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.

The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website and on .

The company’s annual report for the financial year ended December 31, 2022 is now available on its website /investors/financial-reports.

Agenda

The agenda includes the discussion and adoption of the annual accounts for the 2022 financial year, an advisory vote on the company’s 2022 remuneration report, the discharge of the directors for their duties performed in 2022, the proposal to re-appoint Mr. Don deBethizy to the Board of Directors for a period of two years, renewal of the authorization of the Board of Directors to issue shares and to limit or exclude pre-emptive rights in relation thereto, the proposal to appoint Deloitte Accountants B.V. as the company’s external auditor for the 2023 financial year.

The full agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing . argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.

About argenx 

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, the EU and the UK. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on , , and . 

For further information, please contact:  

Media:

Erin Murphy

Investors:

Beth DelGiacco



EN
17/03/2023

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Michiel Declercq
  • Wim Lewi
ARGX ARGEN-X SE
JDEP JDE PEET'S NV
NXFIL NX FILTRATION HLDG BV
08/25/25 August 25, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx Vyvgart meets primary endpoint in snMG paving path for label ex...

argenx announced positive topline data from the pivotal ADAPT SERON study of Vyvgart in AchR-Ab seronegative gMG (snMG), showing a statistically significant improvement vs. placebo (p-value=0.0068) on the primary endpoint of MG-ADL. The positive topline results do not come as a surprise, and confirm previously reported pooled analysis showing improvements in the MG-ADL score in this gMG sub-population. The company plans to file for label expansion with the FDA, and estimates the commercial oppor...

08/25/25 August 25, 2025 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Announces Positive Topline Results from ADAPT SERON Study of VY...

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative Supplemental Biologics License Application (sBLA) to be submitted to U.S. Food and Drug Administration (FDA) by end of 2025 August 25, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving t...

August 25, 2025 1 EN
Free Trial
ARGX ARGEN-X SE

Argen X SE: 1 director

A director at Argen X SE sold 426 shares at 547.910EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

08/19/25 August 19, 2025 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 August 19, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight | Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET. The webinar will be the first of a ‘mini’ series highlighting the argenx pipeline and research and development strategy. argenx management and scientific leadership will be joined by...

August 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch